Treatment of idiopathic pulmonary fibrosis
US12128029B2 · kind B2 · utility
0Cited by
3References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2023 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Dec 20, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.